Generic Name: doravirine

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Company: Merck & Company

Approval Status: Experimental

Generic Version Available: No

Experimental Code: MK-1439

Drug Recommendation

Doravirine has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.

General Info

Doravirine is an HIV medication. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is currently in Phase III clinical trials. It is also being studied as a component of an experimental single-tablet regimen (MK-1439A) that also contains generic versions of tenofovir disoproxil fumarate (TDF) and lamivudine (3TC). Doravirine is an unapproved NNRTI. Test tube studies suggest that it is active against HIV that has become at least partially resistant to currently approved NNRTIs.

However, Merck is currently studying the drug in combination with other HIV medications in people starting HIV treatment for the first time.


Adult Dose: 100mg tablet once a day.

Pediatric Dose: N/A

Dosing Info: N/A

Side Effects


Last Reviewed: January 24, 2016